MedTrace Logo

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis

NCT03634475 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-10-09

Study results available
· View outcomes & findings →

Summary

In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown pre-clinical efficacy in treatment of non-infectious uveitis. PP-001 will be administered to participants as a single intravitreal injection in ascending doses.

Conditions

  • Non-infectious Uveitis

Interventions

DRUG

PP-001

Drug - no placebo

Sponsors & Collaborators

  • Panoptes Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Panoptes Study Director · Panoptes Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-11-30
Completion
2019-04-30

Countries

  • Austria
  • Belgium
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03634475 on ClinicalTrials.gov